NEW YORK, June 11, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
The investigation concerns whether Revance and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 10, 2015, a Class Action lawsuit filed against the company alleges that the Registration Statement issued in connection with the Offering failed to disclose, among other things, that: (i) Revance Therapeutics had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; (ii) Revance Therapeutics did not have the quality or quantity of RT001 on hand sufficient to complete and successful Phase 3 clinical trial. When the true details entered the market, Revance Therapeutics' share price declined and investors suffered damages.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-revance-therapeutics-inc--rvnc-300097886.html
SOURCE Pomerantz LLP
